EE203 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.472
https://www.valueinhealthjournal.com/article/S1098-3015(23)03602-1/fulltext
Title :
EE203 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03602-1&doi=10.1016/j.jval.2023.09.472
First page :
Section Title :
Open access? :
No
Section Order :
12501